Three Neglected-Disease Treatments Newly Added to WHO Essential Medicines List for Paediatric Use

[Geneva, Switzerland – 11 July 2013]
Resulting from DNDi’s paediatric R&D, the treatments will improve the management of deadly malaria, African sleeping sickness, and Chagas disease in children
This week the World Health Organization (WHO) released its newly updated 4th WHO Model List of Essential Medicines for Children (EMLc), in which three treatments developed by the Drugs for Neglected Diseases initiative (DNDi) and its partners have now been included. One treatment was also added to the 18th WHO Model List of Essential Medicines (EML) for adults.

International AIDS Society Conference 2013

[June 30 – July 3, 2013]
7th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention
Kuala Lumpur, Malaysia
The world’s largest open scientific conference on HIV/AIDS was held Kuala Lumpur, Malaysia. DNDi co-hosted a session on closing the treatment gap for children living with HIV.

Ten Years of Health Innovation in Africa: Progress Made But Sustained Engagement and Partnership Needed

[Nairobi, Kenya – 5 June 2013]
Days after two landmark resolutions were adopted at the World Health Assembly – on neglected tropical diseases and on research and development (R&D), financing and coordination for the health needs of developing countries – over 400 scientists, representatives and ministers of health, ambassadors, national control programme representatives, African regulators, health workers, public health experts, and activists from 21 African countries and 10 others from around the world gather in Nairobi to take stock of health innovation for neglected diseases in Africa over the past decade. While progress has been made, and certain diseases are targeted for elimination, the need for strong leadership, coordination, and sustainable funding is as pressing as ever and is critical to achieving much-needed breakthroughs.

A Decade of R&D for Neglected Diseases in Africa

[June 4-5, 2013]
Endemic Country Research and Development for Patient Access
Nairobi, Kenya
On the occasion of DNDi’s 10th anniversary, DNDi and founding partner KEMRI brought together key African decision-makers and public health actors for this special event to explore the challenges and opportunities for research & development for neglected diseases in Africa – past and future!

G-FINDER Report 2012

[3 December,  2012]
This year’s G-FINDER Report provides a survey of global investment into research and development (R&D) of new products for neglected diseases in 2011. Read a comment by Bernard Pécoul on the report’s findings.

DNDi-MMV press release: Open Access Initiative Reveals Drug Hits for Deadly Neglected Tropical Diseases

[Geneva, Switzerland – 13 November 2012]
DNDi screens MMV’s open access Malaria Box, leading to three potential drug classes to treat sleeping sickness and leishmaniasis, which threaten the lives of millions throughout sub-Saharan Africa and pockets around the world
The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) announce today the identification of three chemical series targeting the treatment of deadly neglected tropical diseases (NTDs), through DNDi’s screening of MMV’s open access Malaria Box. The resulting DNDi screening data are among the first data generated on the Malaria Box to be released into the public domain, exemplifying the potential of openly sharing drug development data for neglected patients.

Cipla-DNDi Press Release: WHO Prequalifies A New Artemisinin-Based Combination Treatment (ACT) for Malaria. Artesunate-Mefloquine Fixed-Dose Combination (ASMQ FDC) to be rolled out throughout Asia

[Kuala Lumpur, Malaysia, Mumbai, India, and Geneva, Switzerland – 3 October 2012]
Cipla, one of the leading generic pharmaceutical companies, along with the non-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) today announced the prequalification of the fixed dose combination (FDC) of Artesunate (AS) and Mefloquine (MQ) – ASMQ FDC – by the World Health Organization (WHO). This Cipla-manufactured ASMQ FDC is the first artesunate-mefloquine FDC to be prequalified by WHO and is recommended for the treatment of malaria.
[Malay]

Arcabouço Sustentável de P&D é Necessário para Responder às Necessidades Essenciais de Saúde dos Países em Desenvolvimento

[Genebra, Suíça – 21 de maio de 2012]
A DNDi Dá as Boas-Vindas às Recomendações dos Especialistas da Organização  Mundial da Saúde para Iniciar as Negociações para uma Convenção de P&D na Assembleia Mundial da Saúde
Depois de um processo de uma década de análise e deliberações sobre as formas de melhor atender às necessidades de saúde dos países em desenvolvimento, um relatório divulgado recentemente pelo Grupo Consultivo de Especialistas em Pesquisa e Desenvolvimento: Financiamento e Coordenação (CEWG, na sigla em inglês) será discutido esta semana na 65ª Assembleia Mundial da Saúde (item 13.14 da agenda). A iniciativa Medicamentos para Doenças Negligenciadas (DNDi), uma organização de pesquisa e desenvolvimento (P&D) sem fins lucrativos, dá as boas-vindas à conclusão dos especialistas de que “o tempo chegou para os Estados-Membros da OMS iniciarem um processo conducente à negociação de um acordo vinculativo em P&D relevante para as necessidades de saúde dos países em desenvolvimento”.
[English] [Español]

Marco Sostenible de I + D es Necesario para Responder a Necesidades Esenciales de Salud de los Países en Desarrollo

[Ginebra, Suiza – 21 de mayo de 2012]
DNDi da la Bienvenida a las Recomendaciones de los Expertos de la Organización Mundial de la Salud para Iniciar las Negociaciones para un Convenio de I+D en la Asamblea Mundial de la Salud
Después de una década de un proceso de análisis y discusiones sobre las maneras de satisfacer mejor las necesidades sanitarias de los países en desarrollo, un reciente informe del Grupo Consultivo de Expertos en Investigación y Desarrollo: Financiación Coordinación (CEWG, por sus siglas en inglés) será discutido esta semana en la 65ª Asamblea Mundial de la Salud  (tema 13.14 del programa). La iniciativa Medicamentos para Enfermedades Olvidadas (DNDi), una organización de investigación y desarrollo (I+D) sin fines de lucro, da la bienvenida a la conclusión de los expertos al afirmar que ‘ha llegado el momento de que los Estados Miembros de la OMS pongan en marcha un proceso que lleve a negociar un acuerdo vinculante sobre actividades de I+D que respondan a las necesidades de los países en desarrollo’.
[English] [Português]

Sustainable R&D Framework Needed to Address Essential Health Needs of Developing Countries

[Geneva, Switzerland – 21 May 2012]
DNDi Welcomes World Health Organization Expert Recommendations to Begin Negotiations for an R&D Convention at the World Health Assembly
After a decade-long process of analysis and deliberations on ways to better address the health needs of developing countries, a recently released report of the Consultative Expert Working Group on Research and Development: Financing and Coordination (CEWG) will be discussed this week at the 65th World Health Assembly (agenda item 13.14). The Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development (R&D) organization, welcomes the experts’ conclusion that ‘the time has now come for WHO Member States to begin a process leading to the negotiation of a binding agreement on R&D relevant to the health needs of developing countries’.
[Português] [Español]

Forum 2012: COHRED / Global Forum for Health Research

[April 24-26, 2012]
Cape Town, South Africa
The Council on Health Research and Development Group (The COHRED Group) in collaboration with partners and Governments, launched a new series of Global Forum for Health Research meetings on the theme: ‘Beyond aid…research and innovation as key drivers of health, equity and development’.

Filling R&D Gaps Key to Succeeding in NTD Control and Elimination Goals by 2020

[Geneva, Switzerland – 30 January 2012]
On the occasion of today’s high-level event in London, ‘Uniting to Combat Neglected Tropical Diseases,’ organized in support of the new World Health Organization (WHO) Neglected Tropical Disease (NTD) 2020 Roadmap, the Drugs for Neglected Diseases initiative (DNDi) welcomes the commitments from various partners and emphasizes that filling the major gaps in research and development (R&D) to develop new treatment and diagnostic tools is key to effectively support elimination or control of targeted NTDs by 2020. [Deutsch] [Español] [Português] [Japanese]

Private and Public Partners Unite to Combat 10 Neglected Tropical Diseases by 2020

[London – 30 January 2012]
Partners pledge innovative, coordinated action aimed at new World Health Organisation goals
Today, 13 pharmaceutical companies, the U.S., U.K. and U.A.E governments, the Bill & Melinda Gates Foundation, the World Bank and other global health organisations announced a new, coordinated push to accelerate progress toward eliminating or controlling 10 neglected tropical diseases (NTDs) by the end of the decade.

DNDi and Abbott Expand Partnership to Boost Innovation for Neglected Tropical Diseases

[Geneva, Switzerland – 30 January 2012]
The Drugs for Neglected Diseases initiative (DNDi) and Abbott have signed a four-year joint research and non-exclusive licensing agreement to undertake research on new treatments for several of the world’s most neglected tropical diseases, including Chagas disease, helminth infections, leishmaniasis and sleeping sickness. Through this collaboration, DNDi and Abbott scientists will focus initial efforts on discovering and advancing novel antimicrobial agents with activity against these neglected diseases.

Preencher as Lacunas em P&D é a Chave para Controlar e Eliminar as Doenças Tropicais Negligenciadas

[Geneva, Switzerland – 30 January 2012]
Devido ao evento de alto nível “Unidos para Combater às Doenças Tropicais Negligenciadas”, realizado hoje, em Londres, em apoio ao novo “Roteiro 2020 para as Doenças Tropicais Negligenciadas” da Organização Mundial da Saúde (OMS), a iniciativa Medicamentos para Doenças Negligenciadas (DNDi) dá as boas-vindas aos compromissos de vários parceiros e enfatiza a necessidade de preencher as lacunas em pesquisa e desenvolvimento (P & D) para que se possa desenvolver novos tratamentos e ferramentas de diagnóstico para apoiar de forma eficaz a controlar ou eliminar determinadas doenças negligenciadas até 2020.
[English] [Deutsch] [Español] [Japanese]

Llenar las lagunas en investigación y desarrollo es la clave para controlar y eliminar las enfermedades tropicales olvidadas

[Geneva, Switzerland – 30 January 2012]
Con motivo del evento de alto nivel “Unidos para combatir las enfermedades tropicales olvidadas” organizado en apoyo de la nueva «Hoja de Ruta 2020 para las enfermedades tropicales olvidadas» de la Organización Mundial de la Salud (OMS), la iniciativa Medicamentos para enfermedades Olvidadas (DNDi, por sus siglas en inglés) dio la bienvenida a los nuevos compromisos de varios socios y enfatizó la necesidad de llenar las lagunas en investigación y desarrollo para poder desarrollar nuevas herramientas de diagnóstico y nuevos tratamientos que permitan controlar o eliminar determinadas enfermedades olvidadas para 2020.
[English]
[Deutsch] [Português] [Japanese]